Morgan Stanley Maintains Overweight on Denali Therapeutics, Lowers Price Target to $40

Benzinga Newsdesk www.benzinga.com Negative 89.1%

Neg 89.1% Neu 0% Pos 0%

Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and lowers the price target from $42 to $40.